About Keryx Biopharmaceuticals (NASDAQ:KERX)
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:KERX
- CUSIP: 49251510
- Web: www.keryx.com
Capitalization:- Market Cap: $792.06 million
- Outstanding Shares: 118,750,000
Average Prices:- 50 Day Moving Avg: $7.26
- 200 Day Moving Avg: $6.76
- 52 Week Range: $4.11 - $8.38
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -20.88
- P/E Growth: -0.05
Sales & Book Value:- Annual Revenue: $42.83 million
- Price / Sales: 18.52
- Book Value: $0.22 per share
- Price / Book: 30.36
Profitability:- EBITDA: ($121,750,000.00)
- Net Margins: -431.89%
- Return on Equity: -2,902.87%
- Return on Assets: -78.46%
Debt:- Debt-to-Equity Ratio: 4.88%
- Current Ratio: 5.76%
- Quick Ratio: 5.16%
Misc:- Average Volume: 1.21 million shs.
- Beta: 5.13
- Short Ratio: 12.49
Frequently Asked Questions for Keryx Biopharmaceuticals (NASDAQ:KERX)
What is Keryx Biopharmaceuticals' stock symbol?
Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."
How were Keryx Biopharmaceuticals' earnings last quarter?
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) posted its earnings results on Thursday, July, 27th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.60. The company had revenue of $15.10 million for the quarter, compared to analysts' expectations of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. The firm's quarterly revenue was up 62.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.42) EPS. View Keryx Biopharmaceuticals' Earnings History.
When will Keryx Biopharmaceuticals make its next earnings announcement?
Where is Keryx Biopharmaceuticals' stock going? Where will Keryx Biopharmaceuticals' stock price be in 2017?
5 brokerages have issued 1-year price targets for Keryx Biopharmaceuticals' shares. Their predictions range from $7.00 to $9.00. On average, they expect Keryx Biopharmaceuticals' share price to reach $7.50 in the next twelve months. View Analyst Ratings for Keryx Biopharmaceuticals.
What are analysts saying about Keryx Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Keryx is making efforts to expand the label of Auryxia. With Auryxia being the only approved product in Keryx’s portfolio, the company is entirely dependent on Auryxia for growth. Auryxia faces stiff competition in the U.S. from existing players, apart from over-the-counter drugs like some calcium carbonate and metal-based products. Apart from competition, Keryx may face strong pricing pressure for Auryxia. However, The FDA accepted for review the supplemental New Drug Application (sNDA) for Auryxia tablets for the iron-deficiency anemia (IDA) indication and has set the Prescription Drug User Fee Act (PDUFA) target action date on Nov 6, 2017. A potential approval should increase sales. Shares of the company have outperformed the industry year to date. Estimates have remained stable ahead of the Q3 earnings results. The company has a negative record of earnings surprises in recent quarters." (10/16/2017)
- 2. Maxim Group analysts commented, "Summary Conclusion: We see little to no effect from this news on the commercial outlook for Auryxia." (7/20/2017)
Who are some of Keryx Biopharmaceuticals' key competitors?
Some companies that are related to Keryx Biopharmaceuticals include NovoCure Limited (NVCR), Radius Health (RDUS), AnaptysBio (ANAB), Five Prime Therapeutics (FPRX), MyoKardia (MYOK), Dynavax Technologies Corporation (DVAX), Ascendis Pharma A/S (ASND), Clinigen Group PLC (CLIN), Sangamo Therapeutics (SGMO), Acorda Therapeutics (ACOR), Epizyme (EPZM), Lexicon Pharmaceuticals (LXRX), Dermira (DERM), Xencor (XNCR), REGENXBIO (RGNX), NeuroDerm (NDRM), Athenex (ATNX) and Omeros Corporation (OMER).
Who are Keryx Biopharmaceuticals' key executives?
Keryx Biopharmaceuticals' management team includes the folowing people:
- Michael W. Rogers, Chairman of the Board
- Gregory Paul Madison, Chief Executive Officer, Director
- Scott A. Holmes, Chief Financial Officer, Treasurer
- Christine A. Carberry, Chief Operating Officer
- Douglas M. Jermasek, Vice President of Marketing and Strategy
- Brian R. Adams, General Counsel, Secretary
- Lora Pike, Senior Director
- John F. Neylan, Chief Medical Officer
- Kevin J. Cameron, Independent Director
- Mark J. Enyedy, Independent Director
How do I buy Keryx Biopharmaceuticals stock?
Shares of Keryx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Keryx Biopharmaceuticals' stock price today?
One share of Keryx Biopharmaceuticals stock can currently be purchased for approximately $6.68.
MarketBeat Community Rating for Keryx Biopharmaceuticals (NASDAQ KERX)MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Keryx Biopharmaceuticals (NASDAQ:KERX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 1 Buy Rating |
| Consensus Rating: | Hold (Score: 2.20) |
| Consensus Price Target: | $7.50 (12.28% upside) |
Consensus Price Target History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Analysts' Ratings History for Keryx Biopharmaceuticals (NASDAQ:KERX)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/27/2017 | Maxim Group | Set Price Target | Buy | $9.00 | High |  |
| 7/25/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $4.00 -> $7.00 | Low | |
| 7/25/2017 | Cowen and Company | Reiterated Rating | Market Perform | | Medium | |
| 1/11/2017 | Citigroup Inc. | Upgrade | Sell -> Neutral | $7.00 | N/A | |
| 11/19/2016 | FBR & Co | Reiterated Rating | Hold | | N/A | |
| 9/8/2016 | JMP Securities | Reiterated Rating | Outperform | | N/A | |
| 8/2/2016 | Raymond James Financial, Inc. | Boost Price Target | Outperform | $7.00 -> $10.00 | N/A | |
| 8/2/2016 | Ladenburg Thalmann Financial Services | Boost Price Target | Buy | $9.00 -> $10.00 | N/A | |
| 8/2/2016 | Brean Capital | Downgrade | Buy -> Hold | | N/A | |
| 8/2/2016 | Stifel Nicolaus | Downgrade | Buy -> Hold | | N/A | |
| 3/29/2016 | BTIG Research | Reiterated Rating | Sell | $2.50 | N/A | |
| 2/26/2016 | J P Morgan Chase & Co | Downgrade | Overweight -> Neutral | | N/A | |
(Data available from 10/18/2015 forward)
Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)Earnings History by Quarter for Keryx Biopharmaceuticals (NASDAQ KERX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.17) | | | | | N/A | |
| 7/27/2017 | Q2 2017 | ($0.17) | ($0.77) | $14.51 million | $15.10 million | View | N/A | |
| 5/4/2017 | Q1 2017 | ($0.18) | ($0.21) | $10.19 million | $11.82 million | View | Listen | |
| 3/1/2017 | Q4 2016 | ($0.25) | ($0.32) | $9.65 million | $9.53 million | View | Listen | |
| 11/9/2016 | Q316 | ($0.22) | ($0.39) | $5.53 million | $6.30 million | View | Listen | |
| 8/1/2016 | Q216 | ($0.28) | ($0.42) | $8.60 million | $9.30 million | View | Listen | |
| 4/28/2016 | Q116 | ($0.26) | ($0.39) | $6.63 million | $6.80 million | View | Listen | |
| 2/25/2016 | Q415 | ($0.25) | ($0.36) | $5.68 million | $5.80 million | View | Listen | |
| 10/29/2015 | Q3 2015 | ($0.25) | ($0.29) | $3.91 million | $4.21 million | View | Listen | |
| 8/5/2015 | Q215 | ($0.26) | ($0.26) | $2.86 million | $2.50 million | View | Listen | |
| 5/4/2015 | Q115 | ($0.30) | ($0.28) | $2.45 million | $1.20 million | View | Listen | |
| 2/27/2015 | Q414 | ($0.38) | ($0.44) | $1.70 million | $0.57 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.27) | ($0.38) | $0.39 million | $0.26 million | View | Listen | |
| 8/7/2014 | Q214 | ($0.23) | ($0.24) | $0.28 million | | View | Listen | |
| 5/8/2014 | Q114 | ($0.10) | ($0.15) | $9.91 million | $10.00 million | View | Listen | |
| 3/12/2014 | Q413 | ($0.16) | ($0.21) | $2.22 million | | View | Listen | |
| 11/5/2013 | Q313 | ($0.11) | ($0.19) | $2.22 million | | View | Listen | |
| 8/1/2013 | Q2 2013 | ($0.10) | ($0.14) | | | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.01) | ($0.03) | $5.83 million | $7.00 million | View | Listen | |
| 3/12/2013 | Q4 2012 | ($0.08) | ($0.09) | | | View | Listen | |
| 11/7/2012 | Q312 | ($0.07) | ($0.08) | | | View | N/A | |
| 8/7/2012 | | ($0.09) | ($0.02) | | | View | N/A | |
| 5/8/2012 | | ($0.12) | ($0.13) | | | View | N/A | |
| 2/29/2012 | | ($0.14) | ($0.12) | | | View | N/A | |
| 8/8/2011 | | ($0.03) | ($0.05) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)Current Year EPS Consensus Estimate: $-1.29 EPS
Next Year EPS Consensus Estimate: $-0.32 EPS
Dividend History for Keryx Biopharmaceuticals (NASDAQ:KERX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Keryx Biopharmaceuticals (NASDAQ:KERX)Insider Ownership Percentage: 2.58%
Institutional Ownership Percentage: 65.19%
Insider Trades by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/5/2017 | Brian Adams | General Counsel | Sell | 630 | $7.19 | $4,529.70 | |
| 10/5/2017 | Greg Madison | Insider | Sell | 895 | $7.19 | $6,435.05 | |
| 7/31/2017 | John F. Neylan | Insider | Sell | 1,445 | $7.14 | $10,317.30 | |
| 7/28/2017 | Scott A. Holmes | CFO | Sell | 1,236 | $6.96 | $8,602.56 | |
| 7/24/2017 | John F. Neylan | Insider | Sell | 1,214 | $7.27 | $8,825.78 | |
| 7/5/2017 | Brian Adams | General Counsel | Sell | 641 | $7.67 | $4,916.47 | |
| 7/5/2017 | Greg Madison | Insider | Sell | 910 | $7.67 | $6,979.70 | |
| 4/28/2017 | Scott A. Holmes | CFO | Sell | 1,219 | $5.89 | $7,179.91 | |
| 4/24/2017 | John F. Neylan | Insider | Sell | 1,209 | $5.73 | $6,927.57 | |
| 4/17/2017 | Brian Adams | General Counsel | Sell | 1,090 | $5.75 | $6,267.50 | |
| 4/5/2017 | Brian Adams | General Counsel | Sell | 642 | $5.80 | $3,723.60 | |
| 4/5/2017 | Greg Madison | Insider | Sell | 911 | $5.80 | $5,283.80 | |
| 1/30/2017 | Brian Adams | General Counsel | Sell | 6,984 | $4.65 | $32,475.60 | |
| 1/30/2017 | Greg Madison | Insider | Sell | 18,248 | $4.65 | $84,853.20 | |
| 1/30/2017 | Scott A. Holmes | CFO | Sell | 8,447 | $4.65 | $39,278.55 | |
| 1/23/2017 | John F. Neylan | Insider | Sell | 1,428 | $5.39 | $7,696.92 | |
| 1/17/2017 | Brian Adams | VP | Sell | 1,265 | $6.24 | $7,893.60 | |
| 1/5/2017 | Brian Adams | VP | Sell | 759 | $6.16 | $4,675.44 | |
| 1/5/2017 | Greg Madison | Insider | Sell | 1,077 | $6.16 | $6,634.32 | |
| 10/28/2016 | Scott A. Holmes | CFO | Sell | 1,237 | $4.44 | $5,492.28 | |
| 10/24/2016 | John F. Neylan | Insider | Sell | 1,211 | $4.72 | $5,715.92 | |
| 10/17/2016 | Brian Adams | VP | Sell | 1,106 | $4.86 | $5,375.16 | |
| 10/5/2016 | Brian Adams | VP | Sell | 647 | $5.38 | $3,480.86 | |
| 10/5/2016 | Greg Madison | Insider | Sell | 917 | $5.38 | $4,933.46 | |
| 8/9/2016 | Greg Madison | Insider | Sell | 1,622 | $4.22 | $6,844.84 | |
| 7/29/2016 | Scott A. Holmes | CFO | Sell | 4,935 | $7.36 | $36,321.60 | |
| 7/25/2016 | John F. Neylan | Insider | Sell | 1,217 | $7.43 | $9,042.31 | |
| 7/15/2016 | Brian Adams | VP | Sell | 1,083 | $7.01 | $7,591.83 | |
| 7/5/2016 | Brian Adams | VP | Sell | 660 | $6.66 | $4,395.60 | |
| 7/5/2016 | Greg Madison | CEO | Sell | 936 | $6.66 | $6,233.76 | |
| 5/9/2016 | Greg Madison | CEO | Sell | 1,873 | $5.42 | $10,151.66 | |
| 4/25/2016 | John F Neylan | Insider | Sell | 4,766 | $5.21 | $24,830.86 | |
| 4/15/2016 | Brian Adams | VP | Sell | 1,060 | $5.05 | $5,353.00 | |
| 4/5/2016 | Brian Adams | VP | Sell | 759 | $4.50 | $3,415.50 | |
| 4/5/2016 | Greg Madison | CEO | Sell | 1,078 | $4.50 | $4,851.00 | |
| 2/9/2016 | Greg Madison | CEO | Sell | 1,938 | $3.23 | $6,259.74 | |
| 1/15/2016 | Brian Adams | VP | Sell | 1,322 | $3.30 | $4,362.60 | |
| 1/6/2016 | Brian Adams | VP | Sell | 3,004 | $5.16 | $15,500.64 | |
| 1/6/2016 | Greg Madison | CEO | Sell | 4,261 | $4.83 | $20,580.63 | |
| 11/4/2015 | Scott A. Holmes | CFO | Buy | 5,000 | $5.33 | $26,650.00 | |
| 10/15/2015 | Brian Adams | VP | Sell | 1,011 | $4.01 | $4,054.11 | |
| 8/21/2015 | Scott A Holmes | CFO | Buy | 5,000 | $5.72 | $28,600.00 | |
| 7/15/2015 | Brian Adams | VP | Sell | 1,086 | $9.99 | $10,849.14 | |
| 7/6/2015 | James F Oliviero III | CFO | Sell | 1,943 | $9.61 | $18,672.23 | |
| 5/6/2015 | Michael P Tarnok | Director | Buy | 10,000 | $9.73 | $97,300.00 | |
| 4/15/2015 | Brian Adams | VP | Sell | 4,320 | $12.40 | $53,568.00 | |
| 4/6/2015 | James F Oliviero III | CFO | Sell | 1,878 | $11.68 | $21,935.04 | |
| 4/6/2015 | Ron Bentsur | CEO | Sell | 1,592 | $11.68 | $18,594.56 | |
| 3/6/2015 | Greg Madison | COO | Buy | 6,380 | $12.53 | $79,941.40 | |
| 2/9/2015 | Greg Madison | COO | Sell | 6,759 | $10.95 | $74,011.05 | |
| 1/5/2015 | James F Oliviero III | CFO | Sell | 5,604 | $13.79 | $77,279.16 | |
| 1/5/2015 | Ron Bentsur | CEO | Sell | 5,574 | $13.79 | $76,865.46 | |
| 12/30/2014 | Ron Bentsur | CEO | Sell | 200,000 | $14.11 | $2,822,000.00 | |
| 12/29/2014 | Ron Bentsur | CEO | Sell | 338,977 | $13.98 | $4,738,898.46 | |
| 10/6/2014 | Ron Bentsur | CEO | Sell | 70,838 | $15.88 | $1,124,907.44 | |
| 10/3/2014 | James F Oliviero III | CFO | Sell | 2,694 | $16.14 | $43,481.16 | |
| 9/12/2014 | Ron Bentsur | CEO | Sell | 50,000 | $14.24 | $712,000.00 | |
| 9/8/2014 | James F Oliviero III | CFO | Sell | 144,237 | $15.88 | $2,290,483.56 | |
| 7/7/2014 | James F Oliviero III | CFO | Sell | 2,054 | $15.75 | $32,350.50 | |
| 7/7/2014 | Ron Bentsur | CEO | Sell | 1,788 | $15.75 | $28,161.00 | |
| 4/3/2014 | James Oliviero III | CFO | Sell | 2,087 | $16.46 | $34,352.02 | |
| 4/3/2014 | Ron Bentsur | CEO | Sell | 1,816 | $16.46 | $29,891.36 | |
| 3/21/2014 | James Oliviero III | CFO | Sell | 292,483 | $15.14 | $4,428,192.62 | |
| 1/3/2014 | James Oliviero III | CFO | Sell | 6,309 | $12.57 | $79,304.13 | |
| 1/3/2014 | Ron Bentsur | CEO | Sell | 5,257 | $12.57 | $66,080.49 | |
| 12/30/2013 | James Oliviero III | CFO | Sell | 109,500 | $12.64 | $1,384,080.00 | |
| 10/3/2013 | James Oliviero III | CFO | Sell | 1,475 | $10.25 | $15,118.75 | |
| 10/3/2013 | Ron Bentsur | CEO | Sell | 2,505 | $10.25 | $25,676.25 | |
| 7/5/2013 | James F Oliviero III | CFO | Sell | 1,438 | $7.95 | $11,432.10 | |
| 7/5/2013 | Ron Bentsur | CEO | Sell | 2,440 | $7.95 | $19,398.00 | |
| 5/13/2013 | James F Oliviero III | CFO | Sell | 29,363 | $8.34 | $244,887.42 | |
| 10/3/2012 | James F Oliviero III | CFO | Sell | 4,973 | $2.72 | $13,526.56 | |
(Data available from 1/1/2013 forward)
Headline Trends for Keryx Biopharmaceuticals (NASDAQ:KERX)
Latest Headlines for Keryx Biopharmaceuticals (NASDAQ:KERX)
| Source: |
|
| Date | Headline |
|---|
 | Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : October 16, 2017
finance.yahoo.com - October 16 at 7:43 PM |
 | Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week ... - GlobeNewswire (press release)
globenewswire.com - October 13 at 8:12 PM |
 | Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week 2017 Annual Meeting
feeds.benzinga.com - October 13 at 11:25 AM |
 | KERX Crosses Above Average Analyst Target
www.thestreet.com - October 10 at 7:40 PM |
| Before You Buy Keryx Biopharmaceuticals Inc’s (KERX), You Should Consider This
finance.yahoo.com - October 10 at 7:40 PM |
 | $18.80 Million in Sales Expected for Keryx Biopharmaceuticals, Inc. (KERX) This Quarter
www.americanbankingnews.com - October 10 at 8:48 AM |
 | Why the Bears Are Wrong About Keryx Biopharmaceuticals Stock
www.fool.com - October 10 at 8:00 AM |
| Zacks: Analysts Expect Keryx Biopharmaceuticals, Inc. (KERX) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - October 8 at 2:24 PM |
| Keryx, Upcoming PDUFA Action on Label Expansion for Auryxia
finance.yahoo.com - October 6 at 2:22 AM |
 | Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat
www.zacks.com - September 29 at 9:39 AM |
| Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : September 26, 2017
finance.yahoo.com - September 26 at 10:04 AM |
 | Here's Why These 3 Biotech Stocks Might Stop Rallying (Revised) - Nasdaq
www.nasdaq.com - September 25 at 6:48 PM |
| Keryx Biopharmaceuticals, Inc. (KERX) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - September 24 at 8:34 PM |
| Analyzing Keryx Biopharmaceuticals (KERX) & Its Rivals
www.americanbankingnews.com - September 24 at 10:20 AM |
| Here's Why These 3 Biotech Stocks Might Stop Rallying - Nasdaq
www.nasdaq.com - September 21 at 8:37 AM |
| Here's Why These 3 Biotech Stocks Might Stop Rallying
finance.yahoo.com - September 21 at 8:37 AM |
| Critical Analysis: Keryx Biopharmaceuticals (KERX) vs. Its Peers
www.americanbankingnews.com - September 20 at 4:28 AM |
| Keryx Biopharmaceuticals, Inc. (KERX) Expected to Post Earnings of -$0.17 Per Share
www.americanbankingnews.com - September 19 at 8:10 PM |
| Keryx Biopharmaceuticals, Inc. (KERX) Catches Eye: Stock Jumps 5.9%
finance.yahoo.com - September 18 at 7:44 PM |
| Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : September 15, 2017
finance.yahoo.com - September 16 at 3:44 AM |
| Keryx Biopharmaceuticals Announces Changes to its Board of Directors
feeds.benzinga.com - September 13 at 4:44 PM |
| Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017 - GlobeNewswire (press release)
globenewswire.com - September 5 at 10:03 PM |
| Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017
finance.yahoo.com - September 5 at 5:01 PM |
| Brokerages Anticipate Keryx Biopharmaceuticals, Inc. (KERX) Will Announce Quarterly Sales of $18.80 Million
www.americanbankingnews.com - September 3 at 8:48 AM |
| Keryx Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:KERX) : September 2, 2017
finance.yahoo.com - September 2 at 2:38 AM |
| Keryx Biopharmaceuticals, Inc. (KERX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - August 30 at 8:36 PM |
| Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : KERX-US : August 29, 2017
finance.yahoo.com - August 29 at 3:22 PM |
| Short Interest in Keryx Biopharmaceuticals, Inc. (KERX) Drops By 8.1%
www.americanbankingnews.com - August 27 at 4:04 AM |
| ETFs with exposure to Keryx Biopharmaceuticals, Inc. : August 11, 2017
finance.yahoo.com - August 12 at 1:31 AM |
 | Keryx Biopharmaceuticals: Catalyst In Upcoming FDA Decision - Seeking Alpha
seekingalpha.com - August 10 at 5:00 AM |
| Captain Keryx Beams Up Sales
seekingalpha.com - August 8 at 12:37 AM |
| Keryx Biopharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : KERX-US : August 7, 2017
finance.yahoo.com - August 7 at 7:36 PM |
| Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 5 at 8:56 PM |
| Keryx Biopharmaceuticals to Webcast its Presentation at Canaccord Genuity’s 37th Annual Growth Conference on August 9, 2017
finance.yahoo.com - August 4 at 11:47 PM |
| John F. Neylan Sells 1,445 Shares of Keryx Biopharmaceuticals, Inc. (KERX) Stock
www.americanbankingnews.com - August 1 at 8:22 PM |
| Commit To Purchase Keryx Biopharmaceuticals At $4, Earn 13.8% Using Options
www.nasdaq.com - August 1 at 12:39 AM |
| Keryx Biopharmaceuticals' (KERX) CEO Greg Madison on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - July 29 at 12:58 AM |
| Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat
finance.yahoo.com - July 29 at 12:58 AM |
| Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017
finance.yahoo.com - July 29 at 12:58 AM |
| $17.58 Million in Sales Expected for Keryx Biopharmaceuticals, Inc. (KERX) This Quarter
www.americanbankingnews.com - July 28 at 1:59 PM |
| Keryx (KERX) Posts Wider-than-Expected Q2 Loss, Sales Beat - Nasdaq
www.nasdaq.com - July 28 at 1:13 AM |
| Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and Increased 2017 U.S. Product Sales Guidance
finance.yahoo.com - July 28 at 1:13 AM |
| Keryx (KERX) Posts Wider-than-Expected Q2 Loss, Sales Beat
finance.yahoo.com - July 28 at 1:13 AM |
| Edited Transcript of KERX earnings conference call or presentation 27-Jul-17 12:00pm GMT
finance.yahoo.com - July 28 at 1:13 AM |
| ETFs with exposure to Keryx Biopharmaceuticals, Inc. : July 27, 2017
finance.yahoo.com - July 28 at 1:13 AM |
| Keryx Biopharma reports 2Q loss
finance.yahoo.com - July 28 at 1:13 AM |
| Keryx Biopharmaceuticals, Inc. (KERX) Releases Quarterly Earnings Results, Misses Estimates By $0.60 EPS
www.americanbankingnews.com - July 28 at 12:21 AM |
| Keryx Biopharmaceuticals, Inc. (KERX) Earns "Equal Weight" Rating from Morgan Stanley
www.americanbankingnews.com - July 25 at 8:17 PM |
| Keryx Biopharmaceuticals, Inc. (KERX) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - July 25 at 12:12 PM |
| What to Expect from Keryx (KERX) this Earnings Season?
finance.yahoo.com - July 22 at 5:15 AM |
Keryx Biopharmaceuticals (KERX) Chart for Wednesday, October, 18, 2017
